ClearPoint Neuro Inc (CLPT)

NASD · Healthcare · Medical Devices · USA

ClearPoint Neuro Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

ClearPoint Neuro manufactures guidance systems and therapeutic devices for neurosurgery, including platforms for brain procedures with MRI navigation and laser ablation technology. Through its acquisition of IRRAS Holdings, the company also offers fluid management solutions for neurocritical care. Additionally, ClearPoint provides consulting services to pharmaceutical partners developing therapies for brain delivery.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the ClearPoint Neuro Inc stock.

Our verdict on CLPT

Overvalued: intrinsic value $1.23 per share, market price $7.86, margin of safety -539.1% (as of 2026-11-17).

A 0.9x revenue multiple, discounted for its losses, values the shares at $1.23; the price of $7.86 is 539% above that value.

ETFs with the most weight in CLPT

16 more funds hold it; the full list is part of the paid plan.

More on CLPT

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than CLPT in Medical Devices

52 more in this industry show a wider margin of safety.

Is CLPT undervalued or overvalued?

CLPT is overvalued (as of the 2026-11-17 close). A 0.9x revenue multiple, discounted for its losses, values the shares at $1.23; the price of $7.86 is 539% above that value.

What is the intrinsic value of CLPT?

$1.23 per share (as of the 2026-11-17 close), against a market price of $7.86. That is a margin of safety of -539.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.